Modified ADAMTS4 molecules and method of use thereof
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
-
Citations
20 Claims
-
1-8. -8. (canceled)
-
9. An isolated, modified ADAMTS4 protein with improved stability compared to an ADAMTS4 protein having an amino acid sequence recited in SEQ ID NO:
- 15, said modified ADAMTS4 protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS;
17, 19, 22, 24, 26, 27, and 46-49. - View Dependent Claims (11, 13, 15)
- 15, said modified ADAMTS4 protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS;
- 10. An isolated polynucleotide, said polynucleotide comprising a nucleotide sequence encoding an isolated, modified ADAMTS4 protein with improved stability compared to a naturally-occurring, full-length ADAMTS4 protein, said modified ADAMTS4 protein differing from the naturally-occurring, full-length ADAMTS4 protein by at least one amino acid.
-
14. A method for producing a modified ADAMTS4 protein, said method comprising:
-
introducing a polynucleotide comprising a nucleotide sequence encoding an isolated, modified ADAMTS4 protein with improved stability compared to a naturally-occurring, full-length ADAMTS4 protein, said modified ADAMTS4 protein differing from the naturally-occurring, full-length ADAMTS4 protein by at least one amino acid, into a host cell;
incubating said host cell under conditions that allow expression of the modified ADAMTS4 protein from the polynucleotide; and
purifying the modified ADAMTS4 protein from the host cell.
-
-
16. A method of identifying an inhibitor of an isolated, modified ADAMTS4 protein with improved stability compared to a naturally-occurring, full-length ADAMTS4 protein, said modified ADAMTS4 protein differing from the naturally-occurring, full-length ADAMTS4 protein by at least one amino acid, said method comprising the steps of:
-
determining the aggrecanase activity of the modified ADAMTS4 protein;
contacting the modified ADAMTS4 protein with a candidate agent;
determining the aggrecanase activity of the modified ADAMTS4 protein in the presence of said candidate agent; and
determining whether said candidate agent affects the activity of the modified ADAMTS4 protein.
-
-
17. A pharmaceutical composition for treating an aggrecanase-related disease, comprising:
-
(a) an inhibitor of an isolated, modified ADAMTS4 protein with improved stability compared to a naturally-occurring, full-length ADAMTS4 protein, said modified ADAMTS4 protein differing from the naturally-occurring, full-length ADAMTS4 protein by at least one amino acid, or an antibody that binds specifically to the isolated, modified ADAMTS4 protein; and
(b) a pharmaceutically acceptable carrier. - View Dependent Claims (18, 19, 20)
-
Specification